Sirtex Medical’s DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres, Setting a New Benchmark in Y-90 for HCC
The DOORwaY90 study met its prespecified co-primary endpoints, achieving a best overall…
Sirtex Receives Expanded CE Mark Approval for SIR-Spheres Y-90 Resin Microspheres
Broadened indication increases access to liver cancer treatment across Europe and CE-marked…
Sirtex Medical’s SIR-Spheres Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma
Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the…
